sitagliptin + empagliflozin

DW1026C2 is a fixed-dose combination (FDC) therapy containing 100 mg of sitagliptin and 25 mg of empagliflozin. Developed by Daewon Pharmaceutical, it is indicated for the treatment of type 2 diabetes mellitus (T2DM) in patients who are inadequately controlled on metformin. The combination utilizes two distinct mechanisms of action: sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases active incretin levels to stimulate insulin secretion and suppress glucagon, while empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, leading to increased urinary glucose excretion. This dual approach provides complementary glycemic control for patients with T2DM.

Brand names

Empasita

Other names

sitagliptin 100 mg / empagliflozin 25 mg